Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[The Epigenetic Regulation of Decitabine Resistance in TP53 -Mutated Myelodysplastic Syndromes: Integrated Analysis Based on RNA-seq and Methylomics].

Zhongguo shi yan xue ye xue za zhi - 1 Dec 2025

Zhang Lan, Ren Yu-Ye, Chen Wei, Hu Wen-Ya, Zhao Chen-Xi, Su Li-Ping

Abstract excerpt

OBJECTIVE: To investigate the effects of TP53 genetic status (wild-type/mutated/null) on the drug resistance of decitabine (DAC) in myelodysplastic syndromes (MDS) and identify key resistance-associated genes. METHODS: Two myeloid cell lines with distinct TP53 status (M-07e: wild-type; SKM-1: mutated;) were treated with gradient DAC concentrations (0-10 μmol/L) for 0-72 h. Cell viability was detected by CCK-8...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Decitabine
Share to DNA Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance

Share to Drug Resistance, Neoplasm

Share to Epigenesis, Genetic

Share to Epigenomics

Share to Myelodysplastic Syndromes

Share to RNA-Seq

Source

Identifiers

PMID: 41502265
DOI: 10.19746/j.cnki.issn.1009-2137.2025.06.019

Genes

TP53
CCK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[The Epigenetic Regulation of Decitabine Resistance in TP53 -Mutated Myelodysplastic Syndromes: Integrated Analysis Based on RNA-seq and Methylomics].PMID 41502265Read ↗

Integrative Multi-Omics Analysis Unveils the Molecular Mechanisms by Which TP53 Mutation Influence Early Decitabine Resistance in Myelodysplastic Syndrome.Semantic proximity Read ↗

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.Semantic proximity Read ↗

[Predict response to decitabine in patients with myelodysplastic syndrome and related neoplasms].Semantic proximity Read ↗

Mechanisms of Resistance to Decitabine in the Myelodysplastic SyndromeSemantic proximity Read ↗

Recurrent transcriptional responses in AML and MDS patients treated with decitabineSemantic proximity Read ↗

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromesSemantic proximity Read ↗

Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemiaSemantic proximity Read ↗

TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches.Semantic proximity Read ↗

Dissection of demethylation and toxicity induced gene expression changes after decitabine treatmentSemantic proximity Read ↗

Targeting DNA Methylation in Leukemia, Myelodysplastic Syndrome, and Lymphoma: A Potential Diagnostic, Prognostic, and Therapeutic ToolSemantic proximity Read ↗

Mutant p53 reactivation and DNA demethylation in the treatment of AML/MDS.Semantic proximity Read ↗

Decitabine and its role in the treatment of hematopoietic malignanciesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.